Recombinant growth hormone therapy for cystic fibrosis in children and young adults

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Thaker, Vidhu ^a   Haagensen, Alexandra L ^b   Carter, Ben ^c   Fedorowicz, Zbys ^d   Houston, Brian W ^e  

^a Haverstraw Pediatrics   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^d Bahrain Branch   (Bahrain)

^e TEESSIDE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GLUCOSE; HUMAN GROWTH HORMONE; INSULIN; PLACEBO; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; GLUCOSE BLOOD LEVEL; RECOMBINANT PROTEIN;

ADULT; ANTIBIOTIC THERAPY; BODY WEIGHT GAIN; CHILD; COST BENEFIT ANALYSIS; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; EXERCISE TOLERANCE; FORCED VITAL CAPACITY; GLUCOSE BLOOD LEVEL; GROWTH DISORDER; HEALTH STATUS; HOSPITALIZATION; HUMAN; LEAN TISSUE; LOW DRUG DOSE; LUNG FUNCTION; LUNG FUNCTION TEST; MUSCLE STRENGTH; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIX MINUTE WALK TEST; SYSTEMATIC REVIEW; TREATMENT DURATION; YOUNG ADULT; ADOLESCENT; BLOOD; BODY HEIGHT; BODY MASS; BODY WEIGHT; COMPLICATION; DIET RESTRICTION; DRUG EFFECTS; META ANALYSIS; METABOLISM; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); VITAL CAPACITY; DRUG EFFECT;

ADOLESCENT; BLOOD GLUCOSE; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; CHILD; CYSTIC FIBROSIS; EXERCISE TOLERANCE; FASTING; HUMAN GROWTH HORMONE; HUMANS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; VITAL CAPACITY; YOUNG ADULT;

EID: 84891698621     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008901.pub2     Document Type: Review

References (88)

1. Hütler M, Schnabel D, Staab D, Tacke A, Wahn U, et al.Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise 2002;34(4):567-72. [CFGD Register: GN125]
2. Schibler A, von der Heiden R, Birrer P, Mullis PE. Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [: GN121b]
3. Schibler A, von der Heiden R, Birrer P, Mullis PE. Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood 2003;88(12):1078-81. [CFGD Register: GN121c]
4. von der Heiden R, Kraemer R, Birrer P, Waldegg G, Mullis PE. Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [: GN121a]
5. Grasemann C, Ratjen F, Schnabel D, Reutershahn E, Vester U, Grasemann H. Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal 2008;31(4):815-21. [CFGD Register: GN127e]
6. Grasemann H, Grasemann C, Schnabel D, Ratjen F. Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology 2006;41 (Suppl 29):335. [CFGD Register: GN127b]
7. Grasemann H, Grasemann C, Schnabel D, Ratjen F. Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD Register: GN127a]
8. Schnabel D, Grasemann C, Staab D, Wollmann H, Ratjen F. A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology 2006;41 (Suppl 29):393. [CFGD Register: GN127c]
9. Schnabel D, Grasemann C, Staab D, Wollmann H, Ratjen F. A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics 2007;119(6):e1230-8. [CFGD Register: GN127d]
10. Geller DE, Anbar RD, Konstan MW, Stalvey MS, Jacobs JR, Bakker B. Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology 2008;43 (Suppl 31):368. [: GN128b]
11. Stalvey MS, Anbar RD, Konstan MW, Jacobs JR, Bakker B, Lippe B, et al.A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology 2012;47(3):252-63. [CFGD Register: GN128c; DOI: 10.1002/ppul.21546; PUBMED: 21905270]
12. Stalvey MS, Geller DE, Anbar RD, Konstan MW, Jacobs JR, Bakker B. Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology 2007;42 (Suppl 30):393. [CFGD Register: GN128a]
13. Alemzadeh R, Upchurch L, McCarthy V. Anabolic effects of growth hormone treatment in young children with cystic fibrosis. Journal of the American College of Nutrition 1998;17(5):419-24.
14. Darmaun D, Hayes V, Schaeffer D, Welch S, Mauras N. Effects of glutamine and recombinant human growth hormone on protein metabolism in prepubertal children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism 2004;89(3):1146-52. [CFGD Register: GN90b]
15. Schaeffer D, Darmaun D, Punati J, Mauras N, Hayes VY. Use of glutamine and recombinant human growth hormone (RHGH) in children with cystic fibrosis [abstract]. Pediatric Pulmonology 2000;30 (Suppl 20):323. [: GN90a]
16. Eubanks V, Atchison J, Arani R, Clancy JP, Sorscher EJ, Wooldridge N, et al.Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients [abstract]. Pediatric Pulmonology 2000; Vol. 30 (Suppl 20):322-3. [CFGD Register: GN86a; CRS-ID: 5500100000001740]
17. Eubanks V, Koppersmith N, Wooldridge N, Clancy JP, Lyrene R, Arani RB, et al.Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics 2002;140(4):439-44. [CFGD Register: GN86b; CRS-ID: 5500100000002066]
18. Hardin DS, Sy JP. Effects of growth hormone treatment in children with cystic fibrosis: the National Cooperative Growth Study experience. Journal of Pediatrics 1997;131(1 Pt 2):S65-9. [PUBMED: 9255232]
19. Hardin DS, Stratton R, Kramer JC, Reyes de la Rocha S, Govaerts K, Wilson DP. Growth hormone improves weight velocity and height velocity in prepubertal children with cystic fibrosis. Hormone and Metabolic Research 1998;30(10):636-41. [PUBMED: 9851673]
20. Hardin DS, Ferkol T, Ahn C, Dreimane D, Dyson M, Morse M, et al.A retrospective study of growth hormone use in adolescents with cystic fibrosis. Clinical Endocrinology 2005;62(5):560-6. [PUBMED: 15853825]
21. Huseman CA, Colombo JL, Brooks MA, Smay JR, Greger NG, Sammut PH, et al.Anabolic effect of biosynthetic growth hormone in cystic fibrosis patients. Pediatric Pulmonology 1996;22(2):90-5. [PUBMED: 8875581]
22. Kissner DG. Role of progestational agents in the treatment of undernourished patients with cystic fibrosis [letter]. Pediatric Pulmonology 2000;29(3):244. [CFGD Register: GN93; CRS-ID: 5500100000001942]
23. Marchand V, Baker SS, Baker RD. Leptin level in children with cystic fibrosis, effect megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition 1999;29:512. [CFGD Register: GN94b; CRS-ID: 5500100000002076]
24. Marchand V, Baker SS, Stark TJ, Baker RD. Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 2000;31(3):264-9. [CFGD Register: GN94a; CRS-ID: 5500100000001905]
25. Sackey AH, Taylor CJ, Barraclough M, Wales J, Pickering M. Growth hormone as a nutritional adjunct in cystic fibrosis: results of a pilot study. Journal of Human Nutrition 1995;8(3):185-91.
26. Safai-Kutti S, Selin E, Larsson S, Jagenburg R, Denfors I, Sten G, et al.Zinc therapy in children with cystic fibrosis. Beitrage Zur Infusiontherapie 1991;27:104-14. [CFGD Register: GN36; CRS-ID: 5500100000000479]
27. Vanderwel M, Hardin DS. Growth hormone normalizes pubertal onset in children with cystic fibrosis. Journal of Pediatric Endocrinology & Metabolism 2006;19(3):237-44. [PUBMED: 16607924]
28. Bucuvalas JC, Chernausek SD, Alfaro MP, Krug S, Ritschel W, Wilmott RW. Insulin-like growth factor -I enhances linear growth in undernourished prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology 1998;26 (Suppl 17):355. [CFGD Register: GN123a; CRS-ID: 5500100000001298]
29. Bucuvalas JC, Chernausek SD, Alfaro MP, Krug SK, Ritschel W, Wilmott RW. Effect of insulin-like growth factor-1 treatment in children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 2001;33(5):576-81. [CFGD Register: GN123b; CRS-ID: 5500100000002045]
30. Hardin DS, Ellis K, McConnell RA, Seilheimer DK. Growth hormone improves lean body mass in prepubertal CF children [abstract]. Pediatric Pulmonology 1998;26(Suppl 17):357. [CFGD Register: GN122a]
31. Hardin DS, Ellis KJ, Dyson M, Rice J, McConnell R, Seilheimer DK. Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism 2001;86(9):4424-8. [CFGD Register: GN122d]
32. Hardin DS, Ellis KJ, Dyson M, Rice J, McConnell R, et al.Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics 2001;139(5):636-42. [CFGD Register: GN122e]
33. Hardin DS, Ellis KJ, McConnel R, Seilheimer DK. Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology 1999;28 (Suppl 19):297. [CFGD Register: GN122b]
34. Hardin DS, Rice J, Ahn C, Ferkol T, Howenstine M, et al.Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics 2005;146(3):324-8. [CFGD Register: GN122h]
35. Hardin DS, Ahn C, Prestidge C, Seilheimer DK, Ellis KJ. Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology & Metabolism 2005;18(6):589-95.
36. Hardin DS, Adams-Huet B, Brown D, Chatfield B, Dyson M, Ferkol T, et al.Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. Journal of Clinical Endocrinology & Metabolism 2006; Vol. 91, issue 12:4925-9. [CFGD Register: GN122j]
37. Hardin DS, Adams-Huet B, Brown D, Chatfield B, Dyson M, et al.Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 2006;91(12):4925-9. [CFGD Register: GN122i]
38. Hardin DS, Rice J, Ahn C, Chatfield B, Dyson M, Howenstein M, et al.Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology 2002;34 (Suppl 24):337. [CFGD Register: GN122f]
39. Schnabel D, Staab D, Tacke A, Brosicke H, Gruters A, Wahm U. Anabolic effects of growth (WH)-therapy in patients with cystic fibrosis (CF) [abstract] [Anabole Effekte der Wachstums(WH)-Therapie bei Patienten mit zystischer Fibrose (CF)]. Monatsschrift fur Kinderheilkunde 1997;145:S40. [: GN124]
40. Phase II Study of Growth Hormone in Children With Cystic Fibrosis. Ongoing study 2001.
41. A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis. Ongoing study 2003.
42. American College of Sports Medicine. ACSM's Guidelines for Exercise Testing and Prescription. 7th Edition. Baltimore: Lippincott, Williams, & Wilkins, 2006.
43. Assael BM, Casazza G, Iansa P, Volpi S, Milani S. Growth and long-term lung function in cystic fibrosis: a longitudinal study of patients diagnosed by neonatal screening. Pediatric Pulmonology 2009;44(3):209-15. [PUBMED: 19230003]
44. Barkhouse LB, Fahey J, Gillespie CT, Cole DE. Quantitating the effect of cystic fibrosis on linear growth by mathematical modelling of longitudinal growth curves. Growth, Development, and Ageing 1989;53(4):185-90. [PUBMED: 2638347]
45. Beker LT, Russek-Cohen E, Fink RJ. Stature as a prognostic factor in cystic fibrosis survival. Journal of the American Dietetic Association 2001;101(4):438-42.
46. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 2002;35(3):246-59.
47. Bryant J, Cave C, Mihaylova B, Chase D, McIntyre L, Gerard K, et al.Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation. Health Technology Assessment 2002;6(18):1-168.
48. Byard PJ. The adolescent growth spurt in children with cystic fibrosis. Annals of Human Biology 1994;21(3):229-40.
49. Cystic Fibrosis Foundation, Bethesda, Maryland . Cystic Fibrosis Foundation Patient Registry. Annual Data Report 2008.
50. Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. Journal of Clinical Epidemiology 1988;41(6):583-91. [PUBMED: 3260274]
51. Cutfield WS, Wilton P, Bennmarker H, Albertsson-Wikland K, Chatelain P, Ranke MB, et al.Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000;355(9204):610-3. [PUBMED: 10696981]
52. Dalzell AM, Shepherd RW, Dean B, Cleghorn GJ, Holt TL, Francis PJ. Nutritional rehabilitation in cystic fibrosis: a 5 year follow-up study. Journal of Pediatric Gastroenterology and Nutrition 1992;15(2):141-5.
53. De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, et al.Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. Journal of Clinical Investigation 1997;99(4):643-50. [PUBMED: 9045866]
54. Deeks JJ, Higgins JPT, Altman DG, on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
55. Farrell PM, Kosorok MR, Rock MJ, Laxova A, Zeng L, Lai HC, et al.Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics 2001;107(1):1-13. [PUBMED: 11134427]
56. Gee L, Abbott J, Conway S, Etherington C, Webb A. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax 2000;55(11):946-54.
57. Giovannucci E, Haiman CA, Platz EA, Hankinson SE, Pollak MN, Hunter DJ. Dinucleotide repeat in the insulin-like growth factor-I gene is not related to risk of colorectal adenoma. Cancer Epidemiology, Biomarkers and Prevention 2002;11(11):1509-10.
58. Haeusler G, Frisch H, Waldhor T, Gotz M. Perspectives of longitudinal growth in cystic fibrosis from birth to adult age. European Journal of Pediatrics 1994;153(3):158-63.
59. Hardin DS. GH improves growth and clinical status in children with cystic fibrosis -- a review of published studies. European Journal of Endocrinology / European Federation of Endocrine Societies 2004;151(Suppl 1):S81-5.
60. Higgins JPT, Altman DG, on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
61. Higgins JPT, Deeks JJ, Altman DG, on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
62. Jeffcoate W. Growth hormone therapy and its relationship to insulin resistance, glucose intolerance and diabetes mellitus: a review of recent evidence. Drug Safety 2002;25(3):199-212.
63. Karlberg J, Kjellmer I, Kristiansson B. Linear growth in children with cystic fibrosis. I. Birth to 8 years of age. Acta Paediatrica Scandinavica 1991;80(5):508-14. [PUBMED: 1872173]
64. Kawchak DA, Zhao H, Scanlin TF, Tomezsko JL, Cnaan A, Stallings VA. Longitudinal, prospective analysis of dietary intake in children with cystic fibrosis. Journal of Pediatrics 1996;129(1):119-29. [PUBMED: 8757571]
65. Konstan MW, Butler SM, Wohl ME, Stoddard M, Matousek R, Wagener JS, et al.Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. Journal of Pediatrics 2003;142(6):624-30.
66. Lai HC, Kosorok MR, Sondel SA, Chen ST, FitzSimmons SC, Green CG, et al.Growth status in children with cystic fibrosis based on the National Cystic Fibrosis Patient Registry data: evaluation of various criteria used to identify malnutrition. Journal of Pediatrics 1998;132(3 Pt 1):478-85. [PUBMED: 9544905]
67. Laursen EM, Lanng S, Rasmussen MH, Koch C, Skakkebaek NE, Muller J. Normal spontaneous and stimulated GH levels despite decreased IGF-I concentrations in cystic fibrosis patients. European Journal of Endocrinology / European Federation of Endocrine Societies 1999;140(4):315-21. [PUBMED: 10097250]
68. Lucidi V, Alghisi F, Raia V, Russo B, Valmarana L, Valmarana R, et al.Growth assessment of paediatric patients with CF comparing different auxologic indicators: A multicentre Italian study. Journal of Pediatric Gastroenterology and Nutrition 2009;49(3):335-42. [PUBMED: 19543116]
69. Morison S, Dodge JA, Cole TJ, Lewis PA, Coles EC, Geddes D, et al.Height and weight in cystic fibrosis: a cross sectional study. UK Cystic Fibrosis Survey Management Committee. Archives of Disease in Childhood 1997;77(6):497-500. [PUBMED: 9496182]
70. O'Rawe A, McIntosh I, Dodge JA, Brock DJ, Redmond AO, Ward R, et al.Increased energy expenditure in cystic fibrosis is associated with specific mutations. Clinical Science 1992;82(1):71-6. [PUBMED: 1310920]
71. O'Riordan SM, Dattani MT, Hindmarsh PC. Cystic fibrosis-related diabetes in childhood. Hormone Research in Paediatrics 2010;73(1):15-24. [PUBMED: 20190536]
72. Patel L, Dixon M, David TJ. Growth and growth charts in cystic fibrosis. Journal of the Royal Society of Medicine 2003;96(Suppl 43):35-41.
73. Phung OJ, Coleman CI, Baker EL, Scholle JM, Girotto JE, Makanji SS, et al.Recombinant human growth hormone in the treatment of patients with cystic fibrosis. Pediatrics 2010;126(5):e1211-26. [PUBMED: 20921071]
74. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8.
75. Ratjen F, Döring G. Cystic Fibrosis. Lancet 2003;361(9358):681-9.
76. Reilly JJ, Edwards CA, Weaver LT. Malnutrition in children with cystic fibrosis: the energy-balance equation. Journal of Pediatric Gastroenterology and Nutrition 1997;25(2):127-36.
77. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen:: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
78. Sermet-Gaudelus I, Souberbielle JC, Azhar I, Ruiz JC, Magnine P, Colomb V, et al.Insulin-like growth factor I correlates with lean body mass in cystic fibrosis patients. Archives of Disease in Childhood 2003;88(11):956-61. [PUBMED: 14612353]
79. Sharma R, Florea VG, Bolger AP, Doehner W, Florea ND, Coats AJ, et al.Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 2001;56(10):746-50.
80. Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Heijerman HG, et al.Nutrition in patients with cystic fibrosis: a European Consensus. Journal of Cystic Fibrosis 2002;1(2):51-75.
81. Sterne JAC, Egger M, Moher D, on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
82. Stettler N, Kawchak DA, Boyle LL, Propert KJ, Scanlin TF, Stallings VA, et al.Prospective evaluation of growth, nutritional status, and body composition in children with cystic fibrosis. American Journal of Clinical Nutrition 2000;72(2):407-13. [PUBMED: 10919935]
83. Tanner JM. Growth at Adolescence. Springfield, IL: Charles C Thomas, 1962.
84. Taylor AM, Bush A, Thomson A, Oades PJ, Marchant JL, Bruce-Morgan C, et al.Relation between insulin-like growth factor-I, body mass index, and clinical status in cystic fibrosis. Archives of Disease in Childhood 1997;76(4):304-9. [PUBMED: 9166020]
85. Verhelst J, Abs R. Long-term growth hormone replacement therapy in hypopituitary adults. Drugs 2002;62(16):2399-412.
86. Wiedemann B, Paul KD, Stern M, Wagner TO, Hirche TO. Evaluation of body mass index percentiles for assessment of malnutrition in children with cystic fibrosis. European Journal of Clinical Nutrition 2007;61(6):759-68. [PUBMED: 17213872]
87. Melmed S, Polonsky K, ReedLarsen P, Kronenberg H. Williams Textbook of Endocrinology. 12th Edition. St. Louis, Missouri, USA: Elsevier, W.B. Saunders, 2011.
88. Wilson TA, Rose SR, Cohen P, Rogol AD, Backeljauw P, Brown R, et al.Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. Journal of Pediatrics 2003;143(4):415-21. [PUBMED: 14571209]